Company Description
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.
It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024.
Renovaro Inc. is headquartered in Los Angeles, California.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | David Weinstein |
Contact Details
Address: 2080 Century Park East, Suite 906 Los Angeles, California 90067 United States | |
| Phone | (305) 918-1980 |
| Website | renovarobio.com |
Stock Details
| Ticker Symbol | RENB |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001527728 |
| CUSIP Number | 236078101 |
| ISIN Number | US29350E1047 |
| Employer ID | 45-2259340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Serhat Gümrükcü | Co-Founder and Inventor |
| Simon Tarsh | Interim Chief Financial Officer |
| Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 29, 2024 | 8-K/A | [Amend] Current report |
| Oct 28, 2024 | 10-K/A | [Amend] Annual report |
| Oct 24, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 16, 2024 | 8-K | Current Report |
| Oct 10, 2024 | 10-K | Annual Report |
| Oct 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Sep 17, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 10-Q/A | [Amend] Quarterly report |